The human MxA protein can be detected in the cytoplasm of IFN-alptreated cells, whereas other cytokines, induding IFN-y, are poor inducers. Because IFN-a/B is predominantly synthesized in response to viral infections, MxA ptotein should be detectable in virally infected tissue. Biopsy specimens (n = 64) of 12 different dermatoses were therefore screened with an MxA-specific monoclonal antibody on formalin-fmed, pataffin-embedded and microwave-treated tissue sections. As expected, high amounts of MxA protein were found in acute viral skin lesions (chickenpox, Herpes zoster, and Herpes labialis). In addition, MxA protein was also detected in some inflamma tory skin lesions of unknown etiology (lupus erythematosus, lichen planus, Schoen-
Introduction
Interferons (IFNs) are cytokines with potent anti-viral activity. They are synthesized and secreted in response to viral infections and mediate their biological effect via specific cell surface receptors of target cells. Receptor binding of IFN triggers the synthesis of about 50 effector proteins. Only a few of these proteins have been studied in detail. The Mx proteins (1) are found in all vertebrates analyzed thus far (2, 3) . In human cells, two IFN-inducible genes encode Mx proteins designated MxA and MxB (4,5). The human MxA protein is expressed in the cytoplasm and exhibits intrinsic anti-viral activity against certain negative-strand viruses (6) (7) (8) . In vivo, Mx proteins are synthesized in response to either endogenous IFN (released during viral infections) or treatment with IFN-alP Other cytokines, including IFN-y, are very poor inducers (9). A characteristic feature of MxA is its stability, the half-life exceeding 48 hr (10). In patients undergoing IFN therapy, MxA protein appears in peripheral blood lymphocytes within 4 hr after IFN-a injection and stays at detectable levels for at least 2 weeks (11, 12) .
In several inflammatory dermatoses of unclear etiology, such as lichen planus or lupus erythematosus, a viral cause or viral triggering has been discussed (13) (14) (15) (16) (17) (18) (19) . We hypothesize that if a virus was involved, MxA should be expressed in the lesion tissue.
In this study we screened skin biopsy specimens from patients 
Materials and Methods
Tissues and Paraffin Blocks. Sixtyfour skin biopsy specimens from patients suffering from 12 different dermatoses [chronic (n = 7) and acute (n = 7) viral lesions, bacterial/mycotic lesions (n = 5), eczema (n = 6), psoriasis (n = 8). lichen planus (n = 8), vasculitis (n = 6), granulomatous disorders (n = 3). lupus erythematosus (n = 5 ) , scleroderma (n = 2), urticaria (n = 3), bullous disorders (n = 4)] were obtained and fixed overnight in 4% neutral buffered formalin. Fixed tissue was dehydrated, infiltrated with and embedded in paraffin wax. Sections (3 pm) were mounted on adhesive-coated glass slides to prevent lifting of tissue sections during the immunohistochemical procedure.
Antibody. The mouse anti-mouse Mx MAb 2C12 crossreacts with the human MxA protein (20) and is described in detail by Staeheli et al. (21) .
Slide Pre-treatment. Tissue sections were rehydrated in a series of graded ethanols. The MAb 2C12 was able to detect only the MxA protein in frozen sections but not in untreated, formalin-fixed tissue material. To unmask the binding site, a microwave pre-treatment of the slides was performed (22). The slides were heated in a microwave oven (Panasonic "-5850) in
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PAVLOVIC, BURG 10 mM citric acid, pH 6.0, three times for 5 min at 100 W. After cooling, the slides were rinsed with distilled water and immec!iately immunatained.
Immunohistochemistry. The mouse MAb 2C12 was used as primary antibody. Alkaline phosphatase and monoclonal anti-allcaline phosphatase (APAAP) were used as the immunohistochemical detection system according to the manufacturers protocol ( -, Glostrup, Denmark). B r i d~ slides were incubated overnight with primary MAb 2C12, followed by incubation with secondary antibody (rabbit anti-mouse) and APAAP, each for 30 min. The procedure was repeated two times. Sections were counterstained with hemalum and mounted with glycerin/gelatin.
Results
Sixty-four skin biopsies of 12 different infectious and non-infectious dermatoses were analyzed for the presence of MxA protein by immunohistochemistry. The observed results are summarized in Tible l. Only cytoplasmic staining of living cells was considered relevant, whereas staining of necrotic materials and detritus, which was often seen, was not regarded as a positive reaction.
Control Experiments
Normal human skin was used as negative control. A transfected monocyte cell line constitutively expressing MxA protein served as positive control (8). Monocytic cells growing in suspension were pelleted, fixed in formalin, embedded in paraffin, and cut as described. In addition, a skin biopsy of an interferon injection site (obtained 15 hr after sc injection of 3 x 106 Iu IFN-a) was treated as described above. Sections were used as a second positive control. In all positive control slides, strong cytoplasmic staining was detectable.
In a further control experiment, anti-MxA-MAb 2C12 was preadsorbed by an excess of recombinant MxA protein. With this preparation the specific staining was barely detectable in the positive control sections. 
Infectious Disorders
Viral Lesions. In acute viral lesions such as Herpes simplex, Herpes zortel; or varicella, moderate to strong staining was observed in the cytoplasm of every cell in the epidermis, dermis, and the inflammatory infiltrate in a l l Seven cases examined (Figure la) . The reaction was strongest in the center of the lesions and diminished towards the periphery. In chronic viral lesions we could not detect MxA protein in a viral acanthoma, a condyloma acuminanun, and two cases of mollusca contagiosa. whereas in three cases of viral acanthomas small quantities of MxA protein were detectable in the epidermis (Figure 1b ).
Non-viral Infections (Bacterial/Mycotic/Parasitic Lesions). MxA protein was not detectable in any of the five cases examined (a metastatic gram-positive sepsis, a mycobacterial infection, a leishmaniasis ( Figure IC) , an acrodermatitis chronica atrophicans, and a dermatomycosis).
Noninfectious Disorders
Eczema. Six cases of eczema were examined (three acute dyshidrotic, three chronic). They were uniformly negative (Figure 2 ).
Psoriasis.
All eight psoriatic lesions were positive for MxA protein. Moderate to strong epidermal staining was always present. In general, the staining was stronger in acute and fainter in chronic lesions. In acute lesions, large quantities of MxA protein were detected in all cells in the epidermis, dermis, and inflammatory infiltrate (Figure 2b ).
Lichen Planus. In all eight cases examined, moderate, predominantly epidermal staining was found. In two acute lesions the lichenoid infiltrate exhibited positive MxA staining as well (Figure 2c ).
Vasculitis.
Among the six cases of vasculitis studied, three were leukocytoclastic and three lymphocytic. In the latter, no positive staining w a s found. However, in leukocytoclastic d t i s there were moderate MxA protein accumulations in the cytoplasm of all cells in the epidermis, dermis, and inflammatory infiltrate. The staining was strongest in one case of leucocytoclastic vasculitis within the scope of Schoenlein-Henoch's anaphylactoid purpura.
Granulomatous Disorders. No MxA protein was detectable in the three cases of granulomatous disorders investigated (one sarcoidosis, two granuloma anulare).
Lupus Erythematosus. Skin biopsies from five cases of lupus erythematosus were analyzed. In all sections, at least moderate and in fresh lesions strong MxA staining of all cells (epidermis, dermis, inflammatory infiltrate) was observed (Figure 2d ).
Scleroderma. In sections of two patients suffering from systemic sclerosis or from morphea, no MxA protein was detectable.
Urticaria. No
MxA protein could be detected in wheals of three patients suffering from urticaria.
Bullous Disorders. Four cases of bullous disorders were analyzed (one porphyria cutanea tarda, one pemphigus vulgaris, one bullous pemphigoid, one pemphigus familiaris benignus chronicus). All of them were negative. 
DiscuSsion
Dermatohistopathologists are often confronted with the question of whether an inflammatory skin lesion is of viral origin. In many cases it is difficult to c o n f i i or exdude viral etiology solely by histopathological methods. Direct staining of viral antigen by immunohistochemical methods is possible in the case of a few viruses and others can be detected by in situ hybridization methods and PCR, but there is still no marker for viral infection in general.
A characteristic k a m e of virus-infected cells is their synthesis and secretion of IFNs in a paracrine fashion. Therefore, the expression of IFN-induced proteins in skin lesions might be indicative of a viral infection. An important prerequisite for an EN-induced protein used as a marker for IFN action is a tight regulation by IFNs but not by other cytokines or other regulatory factors. This is the case for the human MxA protein, its gene being strictly regulated by 9, 23) . Moreover, MxA protein is very stable, which allows its detection even weeks after IFN production has ceased (10-12), whereas direct measurement of IFN is diffhlt because of low concentration and short half-life.
To prove that expression of MxA protein is a u s d diagnostic marker for viral infections, tissue sections of various inflammatory dermatoses with known viral, bacterial, parasitic, or mycotic etiology were analyzed for the presence of the protein. We therefore .:,-11" ., , .' . . -A. sections from (a) eczema, (b) psoriasis, (c) lichen planus, and (d) established an immunohistochemical MxA staining method that can be performed on formalin-fixed, paraffin-embedded tissues.
Figure 2. MxA proteins in non-infectious inflammatory dermatoses. Skin
As expected, moderate to high levels of MxA protein were observed in epidermal, dermal, and inflammatory cells of acute viral lesions. In contrast, sections from chronic viral lesions (e.g., viral papilloma) showed no or only low MxA expression limited to the epidermis. No MxA protein was detected in tissue sections of five cases with bacterial, parasitic or mycotic infections. Summarized, in dermatoses of known infectious origin induction of MxA protein occurred exclusively in acute viral lesions (Figure la) .
We also analyzed skin lesions from inflammatory dermatoses with unknown etiology for the presence of MxA protein. In patients suffering from lupus erythematosus (LE), lichen planus, some forms of vasculitis, and psoriasis, lesion tissues were positive for MxA protein. No expression of this protein was detectable in skin lesions from patients with eczema, granulomatous disorders, scleroderma, urticaria, and bullous dermatoses.
Large amounts of MxA protein in lesions from LE patients were located in the epidermis, dermis, and inflammatory infiltrate (Figure 2d ). Earlier studies have demonstrated elevated levels of serum IFN (24) and increased expression of MxA protein (25) in systemic LE (SE). Since the IFN-alP receptor is expressed on most cell types, the accumulation of MxA protein in the skin is not astonishing. However, two of the five LE patients shown to express high amounts of MxA protein suffered from the cutaneous form of the disease. To our knowledge, induction of IFNs in discoid LE (DLE) has not been previously described. The question arising from our finding is whether the MxA-inducing IFN activity in DLE is produced intralesionally or whether there is systemically circulating IFN in this form of LE as well. The cause of the activation of the IFN system in LE is still unknown. A viral etiology has been widely discussed
The predominantly epidermal MxA staining in lichen planus lesions was of moderate intensity. Nevertheless, it was clearly visible in all lesions examined. In some acute cases staining was also found in the lichenoid infiltrate (Figure 2c ). Although the pathogenesis of lichen planus has not yet been elucidated, there is growing evidence that the primary event is a delayed-type hypersensitivity reaction in which as yet unknown antigens, conceivably viral, play a crucial role (18J9).
Leucocytoclastic vasculitis, e.g., Schoenlein-Henochs anaphylactic purpura, often follows a viral infection which may play a role in the pathogenesis of the disease, since circulating immune complexes are frequently found. It is therefore conceivable that the MxA protein detectable in skin biopsies is a remnant of systemic IFN action during, for example, a respiratory infection.
In psoriasis we always found MxA staining in the epidermis of lesion tissue. In acute psoriatic lesions, cells of the inflammatory infiltrate were also positive for MxA protein (Figure 2c) . A lot of work has been carried out on the pathogenesis and immunology of psoriasis (for review see 26). The IFN system has been analyzed in this context as well. Elevated levels of IFN-a have been found in serum (27) and in fluid from suction blisters (28) of psoriatic patients. Gearing and co-workers (29) found IFN-a in the stratum corneum of psoriatic lesions. However, it lacked biological activity. The MxA staining of psoriatic skin resembles that of acute viral lesions in distribution and intensity, implying the presence of biologically active INF-a/P in the psoriatic plaque. The loss of activity (13) (14) (15) (16) (17) . observed in the corneal layer is therefore most probably due to secondary degradation.
No MxA protein was found in eczema (Figure 2d ). Since the differential diagnosis of eczema vs psoriasis is often difficult, a marker allowing the distinction of these two disorders would constitute a helpful diagnostic tool. Larger series of known psoriatic and eczematous skin lesions will have to be examined to define the distinctional specificity of MxA expression in psoriasis.
